A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.

Exclusion Criteria

• •Prior treatment with any HSP90 or HDAC inhibitor for the treatment of multiple myeloma.
• •Patients with unresolved diarrhea ≥ CTCAE grade 2.
• •Patients with acute or chronic liver disease.
• •Patients using medications that have a relative risk of prolonging the QT interval.
• •Clinically significant cardiac diseases.
• •Patients with known disorders due to a deficiency in bilirubin glucuronidation (e.g. Gilbert's syndrome).
• •Pregnant or lactating women.
• •Fertile women of childbearing potential (WCBP) not using adequate contraception.
• •Male patients whose partners are WCBP, not using adequate contraception.
• •Patients who unwilling or unable to comply with the protocol.
• •Phase Ib part: Peripheral neuropathy ≥ CTCAE grade 1.
• •Phase Ib part: Prior treatment with bortezomib.